Solvonis strengthens PTSD pipeline with new U.S. patent allowance

Solvonis Therapeutics (LSE:SVNS) said it has received a Notice of Allowance from the U.S. Patent and Trademark Office covering a new family of compounds within its SVN-SDN-14 post-traumatic stress disorder (PTSD) discovery programme. The patent milestone enhances the intellectual property protection around the early-stage asset as the company works toward selecting a lead development candidate in the first quarter of 2026.

The newly covered compounds are designed to act across serotonin, dopamine and noradrenaline pathways, while incorporating a mechanism for predictable metabolic deactivation. Solvonis said this approach is intended to provide greater control over pharmacokinetics, potentially enabling safer and more flexible dosing. Management believes these characteristics could improve real-world clinical usability and strengthen both the scientific rationale and commercial appeal of its PTSD programme within the competitive central nervous system (CNS) therapeutics space.

Despite the positive IP development, Solvonis’s overall outlook continues to be constrained by weak financial fundamentals, including the absence of revenue in 2024, ongoing losses and continued cash burn. These pressures are partially mitigated by a low-debt balance sheet. From a market perspective, technical indicators are supportive, with the share price trading above key moving averages and a positive MACD signal, although valuation remains difficult to assess due to the lack of meaningful P/E and dividend yield metrics.

More about Solvonis Therapeutics

Solvonis Therapeutics is a London-headquartered, LSE-listed biopharmaceutical company focused on developing novel small-molecule treatments for high-burden CNS disorders, including addiction, psychiatric and neurological conditions. Its pipeline includes repurposed and newly discovered compounds, led by Phase 3 candidate SVN-001 for severe alcohol use disorder in the UK, SVN-002 preparing for a Phase 2b trial in the US for moderate-to-severe alcohol use disorder, and the preclinical PTSD programme SVN-SDN-14, supported by a broader proprietary CNS compound library.